• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Bioprocess Online: What Makes A Good Therapeutic Cancer Vaccine Antigen?

Feb 13, 2024 | In the News

Click here to view...

Conversations Life Science Leaders Aren’t Having: Global Impact and Innovation – with Steve Reed

Feb 5, 2024 | In the News

Click here to view...

Slice of Healthcare: #32 – Steve Reed, Co-Founder & Chief Executive Officer Of HDT Bio

Jan 31, 2024 | In the News

Click here to view...

Scrip Citeline: Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

Jan 30, 2024 | In the News

Click here to view...

BioSpace: Pricing, Politics and AI To Take Center Stage in 2024

Jan 24, 2024 | In the News

Click here to view...
« Older Entries
Next Entries »

Recent Posts

  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
  • Institutional Biosafety Committee
  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow